2. Academic Validation
  3. PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models

PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models

  • Nat Commun. 2023 Sep 26;14(1):5983. doi: 10.1038/s41467-023-41737-1.
Chun Wai Wong 1 2,  Christos Evangelou 1 2,  Kieran N Sefton # 1 2,  Rotem Leshem # 1 2,  Wei Zhang 1,  Vishaka Gopalan 3,  Sorayut Chattrakarn 1 2,  Macarena Lucia Fernandez Carro 1 2,  Erez Uzuner 1 2,  Holly Mole 1,  Daniel J Wilcock 1,  Michael P Smith 1,  Kleita Sergiou 1,  Brian A Telfer 1,  Dervla T Isaac 4,  Chang Liu 4,  Nicholas R Perl 4,  Kerrie Marie 1,  Paul Lorigan 1 5,  Kaye J Williams 1,  Patricia E Rao 6,  Raghavendar T Nagaraju 1 7,  Mario Niepel 4,  Adam F L Hurlstone 8 9
Affiliations

Affiliations

  • 1 Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT, UK.
  • 2 Lydia Becker Institute of Immunology, The University of Manchester, Manchester, M13 9PT, UK.
  • 3 Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD, 20814, USA.
  • 4 Ribon Therapeutics Inc., 35 Cambridge Park Drive, Suite 300, Cambridge, MA, 02140, USA.
  • 5 Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK.
  • 6 Patricia E. Rao Consulting, Acton, MA, 01720, USA.
  • 7 Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, UK.
  • 8 Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT, UK. [email protected].
  • 9 Lydia Becker Institute of Immunology, The University of Manchester, Manchester, M13 9PT, UK. [email protected].
  • # Contributed equally.
PMID: 37752135 DOI: 10.1038/s41467-023-41737-1
Abstract

Resistance mechanisms to immune checkpoint blockade therapy (ICBT) limit its response duration and magnitude. Paradoxically, Interferon γ (IFNγ), a key cytokine for cellular immunity, can promote ICBT resistance. Using syngeneic mouse tumour models, we confirm that chronic IFNγ exposure confers resistance to immunotherapy targeting PD-1 (α-PD-1) in immunocompetent female mice. We observe upregulation of poly-ADP ribosyl polymerase 14 (PARP14) in chronic IFNγ-treated Cancer cell models, in patient melanoma with elevated IFNG expression, and in melanoma cell cultures from ICBT-progressing lesions characterised by elevated IFNγ signalling. Effector T cell infiltration is enhanced in tumours derived from cells pre-treated with IFNγ in immunocompetent female mice when PARP14 is pharmacologically inhibited or knocked down, while the presence of regulatory T cells is decreased, leading to restoration of α-PD-1 sensitivity. Finally, we determine that tumours which spontaneously relapse in immunocompetent female mice following α-PD-1 therapy upregulate IFNγ signalling and can also be re-sensitised upon receiving PARP14 Inhibitor treatment, establishing PARP14 as an actionable target to reverse IFNγ-driven ICBT resistance.

Figures
Products